Citations

Clear

590 citation(s) found for "Ho, Ben".

Towards event sequence representation, reasoning and visualization for EHR data
Wongsuphasawat, Krist, Clark, Kimberly , Plaisant, Catherine , Tao, Cui , Shneiderman, Ben , Chute, Christopher G.

Mayo Clinic

Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium | January 31, 2012 | Volume: No volume available | Issue: No issue available | Pages: 801-806

10.1145/2110363.2110461 Get It

Estrogen inhibits Dlk1/FA1 production: A potential mechanism for estrogen effects on bone turnover
Abdallah, Basem M. , Bay‐Jensen, Anne‐Christine , Srinivasan, Bhuma, Tabassi, Nadine CB, Garnero, Patrick , Delaissé, Jean‐Marie , Khosla, Sundeep , Kassem, Moustapha , Tabassi, N. Charni-Ben, Khosla, Sundeep , Kassem, Moustapha

Mayo Clinic

Journal of Bone and Mineral Research | June 17, 2011 | Volume: 26 | Issue: 10 | Pages: 2548-2551

10.1002/jbmr.444 | PMID 21681814 Get It

Abstract We have recently identified delta-like 1/fetal antigen 1 (Dlk1/FA1) as a novel regulator of bone mass that functions to mediate bone loss under estrogen deficiency in mice. In this report, we investigated the effects of estrogen (E) deficiency and E replacement on serum (s) levels of Dlk1/FA1 (s-Dlk1FA1) and its correlation with bone turnover markers. s-Dlk1/FA1 and bone turnover markers (serum cross-linked C-telopeptide [s-CTX] and serum osteocalcin) were measured in two cohorts: a group of pre- and postmenopausal women (n = 100) and a group of postmenopausal women, where half had received estrogen-replacement therapy (ERT, n = 166). s-Dlk1/FA1 and s-CTX were elevated in postmenopausal E-deficient women compared with premenopausal E-replete women (both p < 0.001). s-Dlk1/FA1 was correlated with s-CTX (r = 0.30, p < 0.01). ERT in postmenopausal women decreased s-Dlk1/FA1, as well as s-CTX and s-osteoclacin (all p < .0001). Changes in s-Dlk1 were significantly correlated with those observed in s-CTX (r = 0.18, p < 0.05) and s-osteocalcin (r = 0.28, p < 0.001). In conclusion, s-Dlk1/FA1 is influenced by E-deficiency and is correlated with bone turnover. Increased levels of s-Dlk1/FA1 in postmenopausal women may be a mechanism mediating the effects of estrogen deficiency on bone turnover. © 2011 American Society for Bone and Mineral Research
Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11
Ben‐Josef, Edgar , Moughan, Jennifer, Flam, Marshall S., Gunderson, Leonard L., Pollock, Jondavid , Myerson, Robert J., Anne, Rani, Willett, Christopher G. , Ajani, Jaffer A. , Rosenthal, Seth A.

Mayo Clinic

Journal of Clinical Oncology | October 19, 2010 | Volume: 28 | Issue: 34 | Pages: 5061-5066

10.1200/jco.2010.29.1351 | PMID 20956625 Get It

PurposeTo determine whether increased duration of radiation therapy (RT) and overall treatment (RX) time has a detrimental effect in anal cancer.Patients and MethodsData from Radiation Therapy Oncology Group (RTOG) 87-04 and RTOG 98-11 trials were combined to form three treatment groups: RT/fluorouracil (FU)/mitomycin (n = 472), RT/FU/cisplatin (n = 320), and RT/FU (n = 145). Cox proportional hazards models were used with the following variables: RT duration, RT intensity, RX duration, treatment group, age, sex, Karnofsky performance score (KPS), T stage, N stage, and RT dose.ResultsIn the univariate analysis, there was a significant association between RX duration and colostomy failure (CF; hazard ratio [HR] = 1.51; 95% CI, 1.07 to 2.14; P = .02), local failure (HR = 1.52; 95% CI, 1.14 to 2.03; P = .005), locoregional failure (HR = 1.51; 95% CI, 1.15 to 1.98; P = .003), and time to failure (HR = 1.40; 95% CI, 1.10 to 1.79; P = .007). The significance of RX duration was maintained after adjusting for treatment group. In multivariate modeling there was a trend toward an association between RX duration and CF (HR = 1.57; 95% CI, 0.98 to 2.50; P = .06) and a statistically significant association with local failure (HR = 1.96; 95% CI, 1.34 to 2.87; P = .0006). Age, sex, KPS, T stage, N stage, and RT dose, but not RT duration, RT intensity, or RX duration, were found to be statistically significant predictors of OS and colostomy-free survival.ConclusionTotal treatment time, but not duration of radiation therapy, seems to have a detrimental effect on local failure and colostomy rate in anal cancer. Induction chemotherapy may contribute to local failure by increasing total treatment time.
The impact of dual energy CT on pseudo enhancement of kidney lesions
Müller, Jan , Vrtiska, Terri J., Schmidt, Bernhard , Howe, Ben, Buzug, Thorsten M. , Petersilka, Martin, Eusemann, Christian D. , McCollough, Cynthia H.

Mayo Clinic

SPIE Proceedings | March 19, 2010 | Volume: 7622 | Issue: No issue available | Pages: 76223I

10.1117/12.844232 Get It

Violation of the ISNT Rule in Nonglaucomatous Pediatric Optic Disc Cupping
Pogrebniak, Alexander E., Wehrung, Ben, Pogrebniak, Katherine, Shetty, Rajesh , Crawford, Pam

Mayo Clinic

Investigative Opthalmology & Visual Science | January 18, 2010 | Volume: 51 | Issue: 2 | Pages: 890

10.1167/iovs.09-3837 | PMID 19737890 Get It

HLA-DQB1*0602 Determines Disease Susceptibility in a New “Humanized” Multiple Sclerosis Model in HLA-DR15 (DRB1*1501;DQB1*0602) Transgenic Mice
Kaushansky, Nathali , Altmann, Daniel M. , Ascough, Stephanie , David, Chella S., Lassmann, Hans , Ben‐Nun, Avraham

Mayo Clinic

The Journal of Immunology | July 31, 2009 | Volume: 183 | Issue: 5 | Pages: 3531-3541

10.4049/jimmunol.0900784 | PMID 19648275 Get It

Abstract The susceptibility to multiple sclerosis (MS), a chronic neurological autoimmune disease that primarily targets CNS myelin, has long been associated with HLA class-II genes. Although several other HLA and non-HLA disease predisposing alleles have been identified, alleles of the HLA-DR15 haplotype (DRB1*1501, DRB5*0101, and DQB1*0602) remain the strongest susceptibility factor. Many studies have suggested that the HLA-DRB1*1501 allele determines MS-associated susceptibility. However, due to strong linkage disequilibrium within the HLA class II region, it has been difficult to unequivocally determine the relative roles of the DRB1*1501 and DQB1*0602 products. In this study we use HLA class-II transgenic mice to illuminate the relative contributions of the DRB1*1501 and DQB1*0602 alleles or their combination to susceptibility toward a new “humanized” MS-like disease induced by myelin-associated oligodendrocytic basic protein (MOBP). Although many immunological studies have focused overwhelmingly on the role of the HLA-DRB1*1501 product in MS, we show that HLA-DRB1*1501 transgenics are refractory to MOBP disease induction, whereas the HLA-DQB1*0602 transgenics are susceptible via T cells reactive against MOBP15–36 and MOBP55–77 encephalitogenic epitopes. Although both transgenics react against these epitopes, the MOBP15–36- and MOBP55–77-reactive T cells are of Th2-type in HLA-DRB1*1501 transgenics and are pathogenic Th1/Th17 cells in the HLA-DQB1*0602 transgenic mice. This new humanized model of MS further implicates autoimmunity against MOBP in MS pathogenesis, provides the first evidence of pathogenic HLA-DQ-associated anti-myelin autoimmunity, and is the first to offer a rationale for HLA-DQB1*0602 association with MS. These findings have important bearing on the candidacy of the DQB1*0602 allele as a genetic risk factor for MS.
C-Lysine Conjugates: pH-Controlled Light-Activated Reagents for Efficient Double-Stranded DNA Cleavage with Implications for Cancer Therapy
Yang, Wang-Yong, Breiner, Boris, Kovalenko, Serguei V., Ben, Chi, Singh, Mani P., LeGrand, Shauna N., Sang, Qing‐Xiang Amy , Strouse, Geoffrey F. , Copland, John A. , Alabugin, Igor V.

Mayo Clinic

Journal of the American Chemical Society | July 28, 2009 | Volume: 131 | Issue: 32 | Pages: 11458-11470

10.1021/ja902140m | PMID 19637922 Get It

Stability of fentanyl 5 μg/mL diluted with 0.9% sodium chloride injection and stored in polypropylene syringes
McCluskey, Susan V, Graner, Kevin, Kemp, Jesse, Aloumanis, Vasileios, Ben, Michel, Kupiec, Thomas C, Vu, Nicole

Mayo Clinic

American Journal of Health-System Pharmacy | April 22, 2009 | Volume: 66 | Issue: 9 | Pages: 860-863

10.2146/ajhp080255 | PMID 19386950 Get It

Synthesis, NMR, DFT and antimicrobial studies of Zn(II) complexes with N-benzyloxycarbonyl-S-alanine
Mitić, Dragana , Miodragovic, D.U., Sladić, Dušan , Vitnik, Željko , Miodragović, Z.M., Andjelković, Katarina , Radulović, Milanka, Juranić, Nenad

Mayo Clinic

Journal of the Serbian Chemical Society | September 23, 2008 | Volume: 73 | Issue: 8-9 | Pages: 815-824

10.2298/jsc0809815m Get It

In this study, the first complexes of Zn(II) with the N-benzyloxycar- bonyl-S-alaninato ligand (N-Boc-S-ala) were synthesized. The new complexes were characterized by elemental analysis, conductometric measurements, IR, 1H-NMR, 13C-NMR and 2D-NMR spectroscopy. On the basis of the experimental data, tetrahedral geometry of the Zn(II) complexes was proposed. A very good agreement between the NMR and DFT calculated data was obtained. Investigation of antimicrobial activity of the newly synthesized complexes was also performed. It was established that [Zn(N-Boc-S-ala)2] was selective and acts only on Candida albicans.